Search
NGS Banner

Presented at the American Cytogenetics Conference (ACC) 2021, this informative presentation explores transitioning from microarray to the SureSeq™ CLL + CNV NGS panel.

SureSeq: For Research Use Only; Not for Use in Diagnostic Procedures.

Related content

  • Share
You might also be interested in

Low frequency SNV and structural aberration detection in haematological disorders

  • Application: Haematology
Read

Time to change: Transitioning from arrays to NGS in CLL & ID/DD analysis with confidence

  • Application: Haematology, Cytogenetics & rare disease
Read

Transitioning CLL FISH analysis into the molecular biomarker era

  • Application: Haematology
Read

Painless transition from arrays to NGS in constitutional ID and DD analysis

  • Application: Cytogenetics & rare disease
Read

Implementing SureSeq Myeloid and CLL panels for comprehensive genomic profiling of haematological malignancies

  • Application: Haematology
Read
CTA Icon

Stay up-to-date with the latest news from OGT, including new products, support resources, and our DNA Dispatch newsletter

Stay up-to-date